Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03969888 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222
A Phase 2 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
NCT03969888: Completed Phase 2 study, sponsored by AbbVie.
NCT03969888 is a Phase 2 study that has completed, run by AbbVie. The registered enrollment target is 78 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (41% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03969888, a Phase 2 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability, and efficacy of ABBV-3067 given alone and in combination with various doses of ABBV-2222 in adults with Cystic Fibrosis who are homozygous for the F508del mutation.
Primary Outcome
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration and is used as a measure of lung function. Mixed-effect model with repeated measures (MMRM) was used for the analyses.
Interventions
- DRUG ABBV-3067
- DRUG Placebo ABBV-3067
- DRUG ABBV-2222
- DRUG Placebo ABBV-2222
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2019-12-11 |
| Est. Completion | 2022-06-09 |
| Phase | Phase 2 |
What the finished NCT03969888 record still lists
NCT03969888 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (41% lower).
The record links to 0 conditions, and to 4 interventions - of which ABBV-3067 is the first listed.
NCT03969888 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03969888 about?
NCT03969888 is a clinical study titled "A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222". This study will evaluate the safety, tolerability, and efficacy of ABBV-3067 given alone and in combination with various doses of ABBV-2222 in adults with Cystic Fibrosis who are homozygous for the F508del mutation.
What is the current status of trial NCT03969888?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2019-12-11. Estimated completion is 2022-06-09.
What interventions are being tested in trial NCT03969888?
The interventions under investigation include: ABBV-3067 (DRUG), Placebo ABBV-3067 (DRUG), ABBV-2222 (DRUG), Placebo ABBV-2222 (DRUG).
Who is sponsoring clinical trial NCT03969888?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03969888's enrollment target sits among peer trials
78 884th of 2000 higher than 1,110 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI